Tags

Type your tag names separated by a space and hit enter

Expression analysis and study of KLK4 in benign and malignant breast tumours.
Thromb Haemost. 2009 Feb; 101(2):381-7.TH

Abstract

The steroid hormone-regulated gene KLK4 (kallikrein 4) is a new member of the human kallikrein-related peptidase gene family. Up to date, studies report that KLK4 is differentially expressed in many tumours. The purpose of this study was the expression analysis and study of KLK4 in benign and malignant breast tumours. Total RNA was isolated from 16 benign and 45 malignant breast tissue specimens. After testing RNA quality, cDNA was prepared by reverse transcription. Highly sensitive quantitative real-time PCR method for KLK4 mRNA quantification was developed using the SYBR Green chemistry. GAPDH served as a housekeeping gene. Relative quantification analysis was performed using the comparative C(T) method 2(-DeltaDeltaC)(T) KLK4 expression was found to vary in both patients' cohorts; however, a statistically significant elevation of the KLK4 mRNA levels was observed in malignant compared to benign tumour patients. Low KLK4 expression levels were found in well-differentiated tumours (p = 0.011) as well as in stage I (p = 0.024) patients. Moreover, a statistically significant (r(s) = -0.318, p = 0.035) negative correlation between the KLK4 expression and progesterone receptor staining was observed. ROC and logistic regression analysis recommended that KLK4 gene expression may be used as a new potential biomarker in breast cancer.

Authors+Show Affiliations

Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Athens, Panepistimiopolis, 15701 Athens, Greece.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19190825

Citation

Papachristopoulou, Georgia, et al. "Expression Analysis and Study of KLK4 in Benign and Malignant Breast Tumours." Thrombosis and Haemostasis, vol. 101, no. 2, 2009, pp. 381-7.
Papachristopoulou G, Avgeris M, Scorilas A. Expression analysis and study of KLK4 in benign and malignant breast tumours. Thromb Haemost. 2009;101(2):381-7.
Papachristopoulou, G., Avgeris, M., & Scorilas, A. (2009). Expression analysis and study of KLK4 in benign and malignant breast tumours. Thrombosis and Haemostasis, 101(2), 381-7.
Papachristopoulou G, Avgeris M, Scorilas A. Expression Analysis and Study of KLK4 in Benign and Malignant Breast Tumours. Thromb Haemost. 2009;101(2):381-7. PubMed PMID: 19190825.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Expression analysis and study of KLK4 in benign and malignant breast tumours. AU - Papachristopoulou,Georgia, AU - Avgeris,Margaritis, AU - Scorilas,Andreas, PY - 2009/2/5/entrez PY - 2009/2/5/pubmed PY - 2009/3/21/medline SP - 381 EP - 7 JF - Thrombosis and haemostasis JO - Thromb. Haemost. VL - 101 IS - 2 N2 - The steroid hormone-regulated gene KLK4 (kallikrein 4) is a new member of the human kallikrein-related peptidase gene family. Up to date, studies report that KLK4 is differentially expressed in many tumours. The purpose of this study was the expression analysis and study of KLK4 in benign and malignant breast tumours. Total RNA was isolated from 16 benign and 45 malignant breast tissue specimens. After testing RNA quality, cDNA was prepared by reverse transcription. Highly sensitive quantitative real-time PCR method for KLK4 mRNA quantification was developed using the SYBR Green chemistry. GAPDH served as a housekeeping gene. Relative quantification analysis was performed using the comparative C(T) method 2(-DeltaDeltaC)(T) KLK4 expression was found to vary in both patients' cohorts; however, a statistically significant elevation of the KLK4 mRNA levels was observed in malignant compared to benign tumour patients. Low KLK4 expression levels were found in well-differentiated tumours (p = 0.011) as well as in stage I (p = 0.024) patients. Moreover, a statistically significant (r(s) = -0.318, p = 0.035) negative correlation between the KLK4 expression and progesterone receptor staining was observed. ROC and logistic regression analysis recommended that KLK4 gene expression may be used as a new potential biomarker in breast cancer. SN - 0340-6245 UR - https://www.unboundmedicine.com/medline/citation/19190825/Expression_analysis_and_study_of_KLK4_in_benign_and_malignant_breast_tumours_ L2 - https://medlineplus.gov/breastcancer.html DB - PRIME DP - Unbound Medicine ER -